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Investigating the Vascularization of Tissue-Engineered
Bone Constructs Using Dental Pulp Cells
and 45S5 Bioglass Scaffolds
Reem El-Gendy, PhD,1–3 Jennifer Kirkham, PhD,2 Phillipa J. Newby, PhD,4
Yamuna Mohanram, PhD,1 Aldo Roberto Boccaccini, Dr.-Ing,4,5 and Xuebin B. Yang, PhD1
Identification of a suitable cell source combined with an appropriate 3D scaffold is an essential prerequisite for
successful engineering of skeletal tissues. Both osteogenesis and angiogenesis are key processes for bone
regeneration. This study investigated the vascularization potential of a novel combination of human dental pulp
stromal cells (HDPSCs) with 45S5 Bioglass scaffolds for tissue-engineered mineral constructs in vivo and
in vitro. 45S5 Bioglass scaffolds were produced by the foam replication technique with the standard compo-
sition of 45wt% SiO2, 24.5wt% Na2O, 24.5wt% CaO, and 6wt% P2O5. HDPSCs were cultured in monolayers
and on porous 45S5 Bioglass scaffolds under angiogenic and osteogenic conditions for 2–4 weeks. HDPSCs
expressed endothelial gene markers (CD34, CD31/PECAM1, and VEGFR2) under both conditions in the
monolayer. A combination of HDPSCs with 45S5 Bioglass enhanced the expression of these gene markers.
Positive immunostaining for CD31/PECAM1 and VEGFR2 and negative staining for CD34 supported the gene
expression data, while histology revealed evidence of endothelial cell-like morphology within the constructs.
More organized tubular structures, resembling microvessels, were seen in the constructs after 8 weeks of
implantation in vivo. In conclusion, this study suggests that the combination of HDPSCs with 45S5 Bioglass
scaffolds offers a promising strategy for regenerating vascularized bone grafts.
Introduction
Vascularization of tissue-engineered constructs isessential to allow diffusion of oxygen and nutrients to
the constructs’ center, avoiding lack of perfusion that might
otherwise lead to central necrosis.1 It is well known that
vascularization plays a major role in endochondral and in-
tramembranous ossification and is a central requirement for
bone regeneration and fracture healing. Angiogenesis during
bone regeneration is mediated through the angiopoietin or
the vascular endothelial growth factor (VEGF) pathway,
with the latter known to be the most important.2 The iden-
tification of appropriate cells and scaffolds that will allow/
promote angiogenesis and vascular growth within the con-
structs is therefore the determining factor for future clinical
applications in bone tissue engineering.3
Human dental pulp stem/stromal cells (HDPSCs) are a
population of cells present in the pulp, the vital part of adult
and deciduous teeth. They are multipotent, highly prolifera-
tive, and capable of producing mineralized nodules in vitro or
forming a pseudo pulp/dentin complex and/or bone in vivo
depending on the site of implantation.4–6 HDPSCs are known
to express several stem cell surface antigen markers, among
which are vascular-associated and smooth muscle markers,
such as vascular cell adhesion molecule (VCAM), alpha
smooth muscle actin, and melanoma-associated antigen/mu-
cin-18 (MUC-18)/CD146, which identifies stem cells of the
endothelial lineage. The expression of such markers was
thought to be associated with the perivascular niche origins
of HDPSCs.7,8 HDPSCs regenerate and repair the dental
pulp tissue complex. Thus, they are potentially predisposed
to default toward angiogenic differentiation.8–11
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In light of the importance of angiogenesis in wound
healing12 and in both endochondral and intramembranous
ossification,13 the angiogenic potential of HDPSCs in rela-
tion to their osteogenic differentiation has been further in-
vestigated. Many researchers have been interested in
HDPSC-associated angiogenesis as an essential pillar for
pulp regeneration,5,14 others have investigated the use of the
angiogenic potential of these cells in treating ischemic limb
disease.15 However, fewer studies have looked at the com-
bination of their osteogenic/angiogenic properties.16
Silicate bioactive glasses, first investigated by Hench
et al.,17 have been well researched as 3D bone tissue scaf-
folds. The application of bioactive glasses and glass-ceramics
in bone tissue engineering is expanding.18,19 Furthermore,
bioactive glasses can also serve as carriers for the local
delivery of metal ions to control cellular functions.20 The
dissolution products from such glasses can upregulate ex-
pression of genes that control osteogenesis.21,22 In addition,
there is increasing evidence of the positive effects of bio-
active glass on vascularization of tissue engineering con-
structs.22,23 The angiogenic potential of 45S5 Bioglass has
been reported previously, but is not yet well established.24
In the present study, we have investigated the expression
of endothelial cell markers by HDPSCs in monolayer cul-
ture, 3D culture (in combination with porous 45S5 Bioglass
scaffolds), and after in vivo implantation to test the hy-
pothesis that this novel combination might promote and
support construct vascularization.
Materials and Methods
Cell culture plastics were purchased from Corning.
Alpha-modified minimum essential medium (a-MEM),
phosphate-buffered saline solution, and fetal bovine serum
(FBS) were obtained from Lonza. Antibiotics, growth fac-
tors, enzymes, and other reagents were purchased from
Sigma, unless stated otherwise.
Structural characterization of 45S5 Bioglass scaffolds
The starting bioactive glass powder used in these inves-
tigations (45S5 Bioglass) had the standard composition of
45wt% SiO2, 24.5wt% Na2O, 24.5wt% CaO, and 6wt%
P2O5.
17 Scaffolds were produced by the foam replication
technique as described by Chen et al.25 and El-Gendy
et al.26 The sintered scaffolds produced for this work were
subjected to a range of characterization techniques to ensure
that they were comparable with previous work and were
suitable for use in bone tissue engineering.
The scaffolds were examined in the scanning electron
microscope (SEM) to determine the pore dimensions, strut
cross section, and the topography of the scaffold using a
JEOL JSM 5610LV SEM. The overall porosity of the
scaffold was determined using a measure of the scaffold’s
physical dimensions, its mass, and the density of the Bio-
glass powder. The crystalline structure of the scaffold was
measured through X-ray diffraction (XRD) using a Phillips
PW1700 series machine using Cu Ka radiation and the re-
sulting data were processed using X’Pert HighScore com-
bined with the PCPDF data base.
The chemical structure of the scaffold was assessed by de-
ploying Fourier transform infrared spectroscopy (FTIR) using
a Bruker Vector 22 TGA-IR setup to measure transmission
spectra. The mechanical competence of the scaffolds was
measured by ascertaining the compressional strength using a
Zwick testing machine. Surface topography was investigated
using white light interferometry (WLI) and wettability using a
Zygo NewView 200 white light microscope-based inter-
ferometer and a Kruss DSA30 instrument respectively. The
measurements were carried out on cylindrical pellets fabri-
cated using the same conditions employed to fabricate the
scaffolds. The bioactivity of the scaffolds was also assessed by
soaking the scaffolds in simulated body fluid (SBF) for 14
days, prepared in accordance with Kokubo,27 and character-
ized using the techniques described previously in this section
to determine if hydroxyapatite was present as this is themarker
of the bioactive character of the scaffold.
Cell isolation and in vitro expansion
The pulp tissues were collected from three wisdom teeth
from three different donors (1male, 19 years old and 2 females,
20 and 37 years old), with full patient consent and ethical
approval (LREC 07/H1306/93). HDPSCs were isolated using
the collagenase digestion method as previously described.4,28
The cells were maintained in basal medium (a-MEM supple-
mented with 20% FBS, 200mM l-glutamine, and 100 units/
mL penicillin/streptomycin) at 37C and 5% CO2 until 80%
confluent.26 Passage 4 (P4) cells were used for this study.
Human dental pulp stromal cell culture
as monolayers in vitro
HDPSCs were seeded into six-well plates at 5 · 105 cells
per well (n = 3 for each of three donors) and cultured under
basal or osteogenic (basal medium supplemented with
100 nM dexamethasone and 50 mM of l-ascorbic acid-2
phosphate) conditions for up to 2 and 4 weeks. The samples
were then collected for quantitative real-time PCR (qRT-
PCR) to look at endothelial gene expression.
Human dental pulp stromal cell seeding
and growth on 3D scaffolds
HDPSCs (5· 105 cells/scaffold) were dynamically seeded
and cultured on sterile 3D Bioglass scaffolds (5· 5 · 5mm3)
for 5 days using an in-house rotating bioreactor, as previ-
ously described.26 The cell–scaffold constructs were then
statically cultured in basal or osteogenic conditions (n = 3/
donor) at 37C and 5% CO2 for 2 and 4 weeks with weekly
changes of the medium.
Comparing endothelial gene expression of HDPSCs
in monolayers and in 3D cultures using qRT-PCR
Expression of endothelial marker genes (CD34, CD31/
PECAM1, and VEGFR2) was assessed using qRT-PCR.
GAPDH was used as the housekeeping gene. RNA was
extracted using the TRIzol reagent kit (Invitrogen) accord-
ing to the manufacturer’s instructions. One microgram of
RNA from each sample was used for reverse transcription
using the ABI High-Capacity RNA-to-cDNA kit (Applied
Bioscience) according to the supplier’s instructions. cDNA
was then amplified using ABI TaqMan primers (GAPDH:
Hs99999905-m1, CD34: Hs00990732-m1, CD31/PECAM1:
Hs01065279-m1, VEGFR2: Hs00911700-m1) in a 20mL
reaction mix in 96-well plates (Roche). Amplification was
performed using a Roche LC480 cycler.
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The results were analyzed using the 2 -DDct method29
where ct values at each time point were normalized to the
housekeeping gene in the same sample and further normal-
ized to ct values of control samples (cultured under basal
conditions) at the corresponding time points. Results were
then expressed as log mean 2-DDct– standard deviation (SD).
In vivo intraperitoneal implantation of 3D constructs
(45S5 Bioglass scaffolds seeded with HDPSCs)
The diffusion chamber model provides an enclosed space
within the host animal for studies of cellular proliferation/
differentiation of implanted human cells. The filters on the
diffusion chamber allow free exchange of nutrients (in-
cluding many well-known and/or unknown growth factors,
which may be crucial for functional tissue engineering) and
waste, but effectively isolate the experimental cells from the
host tissues.30,31 The in vivo experiments were carried out in
strict accordance with ethical guidelines and UK Home
Office regulations under a project license.
The 3D45S5 Bioglass scaffolds seeded with HDPSCs
were used as the test group (n = 4), and scaffolds without
cells were used as the negative controls (n = 2). The con-
structs (together with the control scaffolds) were dynami-
cally cultured for 5 days, followed by static culture in basal
medium for a further 2 days, before being sealed into dif-
fusion chambers (Millipore) and implanted intraperitoneally
in male immunocompromised nude mice (MF1-Nu/Nu, 4–5
weeks old).32 Mice were sacrificed after 8 weeks according
to UK Home Office regulations. The diffusion chambers were
retrieved and samples were fixed in 10% neutral buffered
formalin before processing for immunohistochemistry.
Immunohistochemical examination
of cell–scaffold constructs
Samples from both in vitro and in vivo studies were par-
affin embedded and sectioned at 5mm. Sections were stained
for immunohistochemistry using primary antibodies directed
against human cluster of differentiation 34 (CD34, mouse
monoclonal, ab8536, 1/100; Abcam), platelet endothelial cell
adhesion molecule 1 (PECAM1, also known as CD31, rabbit
polyclonal, ab28364, 1/100; Abcam), and vascular endothe-
lial growth factor 2 (VEGFR2, rabbit polyclonal, ab28364, 1/
100; Abcam). The Envision kit (Dako) was used to provide
secondary antibodies and substrate in each case. Negative
controls, which were not exposed to primary antibodies, were
included in the study.
Three randomfields fromeach section and three sections from
each sample were recorded and assessed by a blinded opera-
tor. The stain intensity was then semiquantitatively assessed.
Microvessel-like tubular structures were categorized according
to the diameters of their lumens (< 40 and >40mm), which was
due to some capillaries (such as sinusoidal capillaries) having
larger openings (30–40mm in diameter), although most of the
capillaries are about 5–10mm in diameter.33–35 Immunopositive
microvessel-like tubular structures were counted and recorded
for each marker36 using NIS-Elements BR 3.0 software.
Statistical analyses
Each experiment was repeated thrice using cells from
three different donors. Results shown are presented from
one representative donor.
qRT-PCR data were statistically analyzed using a one-
way ANOVA test, followed by Bonferroni multiple com-
parison tests. The statistical analyses were carried out using
the GraphPad Instat software (version 3).
Microvessel-like tubular structure counts were tested for
statistical significance using two-way ANOVA testing
(GraphPad Prism: version 6).
Results
Characterization of the 45S5 Bioglass scaffolds
in preparation for the cell culture work
A standard set of characterization techniques was used to
investigate the properties of these 45S5 Bioglass scaffolds
to ascertain whether they were suitable for the cell cul-
ture work and to prove that they aligned with previous
results.25,26
The porosity of the sintered scaffold was found to average
above 90% with a pore size ranging between *200 and
600mm with a cross-sectional strut size in the range of 25–
75mm, as seen in Figure 1A and C, respectively, consistent
with previously published work on silicate scaffolds fabri-
cated by the same foam replica technique.25,37
Figure 1B shows that the surface of the scaffold had a
rough microtopography, which in previous studies has been
shown to encourage cell attachment38 and, given the in-
creased surface area, accelerates surface reactions.39 The
roughness seen in Figure 1B is further supported by the WLI
and wettability studies. The WLI study produced average
root-mean-square roughness (RMS), roughness average (Ra),
and peak-to-valley (PV) surface roughness values of 3.3– 1.3,
2.6– 0.9, and 19.1– 9.0mm, respectively, and the wettability
study produced a contact angle of 28 – 4. Both sets of re-
sults are in agreement with results in the literature.40
Figure 1D shows the effects of immersion in SBF for 14
days on the surface of the scaffold with the presence of
hydroxyapatite deposits and a decrease in the scaffold’s
porosity to *83%. This effect changes the surface topo-
graphy with the WLI study showing RMS, Ra, and PV
values of 6.3 – 1.4, 5.7 – 1.1, and 25.5 – 8.7 mm, respectively,
and the contact angle from the wettability study being
23 – 3 after immersion in SBF for 14 days; both values fall
in line with the previous experimental results.41
The mechanical competence of the 45S5 Bioglass scaf-
fold was assessed using compressive strength tests, which
gave an average mechanical strength of 0.53 – 0.08 and
0.43 – 0.05MPa before and after immersion in SBF, re-
spectively, which is again consistent with data presented in
previous studies.25,42,43
Figure 1E shows the FTIR spectra of sintered 45S5
Bioglass scaffolds before and after immersion in SBF, and
characteristic bond peaks44,45 are clearly seen in both
spectra. However, the scaffold that was immersed in SBF
for 14 days exhibited signs of hydroxyapatite formation as
seen by the changing shape of the spectra, which is in
agreement with previously published results.46
Figure 1F shows the XRD spectra before and after im-
mersion in SBF for 14 days and confirms the crystalline
nature of the scaffolds with the main crystalline phase being
Na2Ca2Si3O9, which is consistent with previous investiga-
tions.25,47,48 The spectrum corresponding to the scaffold
after immersion in SBF for 14 days shows the presence of
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hydroxyapatite, indicating that the samples are bioactive and
therefore suitable for bone tissue engineering applications.41
Overall, the fabricated foam replicated 45S5 Bioglass-
derived glass–ceramic scaffolds are consistent with the state
of the art for this type of biomaterial and they were therefore
selected to be used in the cell culture section of this study.
The effect of 3D 45S5 Bioglass scaffolds
on the expression of vascular/endothelial marker
genes in HDPSC-Bioglass constructs in vitro
To determine the effect of the 3D 45S5 Bioglass scaffolds
on endothelial marker gene expression by HDPSCs, the levels
of gene expression for HDPSCs cultured under osteogenic
conditions as monolayers were compared with those for
HDPSCs on 3D 45S5 Bioglass scaffolds. The expression was
normalized to corresponding control samples cultured under
basal conditions at 2 and 4 weeks (Fig. 2). The results are
presented in the form of mean log10 2
-DDct–SD as explained
earlier. The HDPSC expression levels of all three endothelial
markers (CD34, CD31/PECAM1, and VEGFR2) were signif-
icantly higher for cells in 3D 45S5 Bioglass constructs com-
pared with the expression of the same markers by HDPSCs
cultured in monolayers ( p< 0.001). There was a significant
decrease in CD34 and CD31/PECAM1 gene expression for
HDPSCs cultured in both 3D constructs and asmonolayers at 4
weeks compared with the expression levels of these genes at 2
weeks ( p< 0.001). In spite of this decrease, the levels of ex-
pression for CD34 and CD31/PECAM1were still significantly
higher ( p< 0.001) in 3D constructs compared with monolayer
cultures at the same time point. However, VEGFR2 showed
significant upregulation ( p< 0.001) in HDPSCs cultured in
monolayers for 4 weeks compared with the downregulation
observed in cells cultured in the 3D constructs.
FIG. 1. Structural characterization of 45S5 Bioglass scaffolds using a scanning electron microscope and spectra analysis.
(A) The overall porosity of the scaffold, (B) the microtopography of the surface of a scaffold, (C) the cross section of a strut
from a 45S5 Bioglass scaffold, (D) the presence of hydroxyapatite on the surface of the scaffold after immersion in
simulated body fluid (SBF) for 14 days, (E) Fourier transform infrared spectroscopy spectra before and after immersion in
SBF for 14 days, and (F) X-ray diffraction spectra before and after immersion in SBF for 14 days. Color images available
online at www.liebertpub.com/tea
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Distribution of positive specific endothelial markers
within HDPC-3D 45S5 Bioglass scaffold constructs
cultured in vitro and in vivo
The distribution of positive immunostaining for endo-
thelial markers within the cell–scaffold constructs following
in vitro culture under basal and osteogenic conditions is
shown in Figure 3. Positive staining was detected for all
three markers in both the basal (Fig. 3A, D, G) and osteo-
genic (Fig. 3B, E, H) culture groups, as well as for the
positive controls (Fig. 3C, F, I). Positively stained cells
demonstrated a flat fibroblastic phenotype rather than the
cuboidal or polygonal cell morphology that might be ex-
pected to indicate a more vascular phenotype. They also
aligned to form microvessel-like tubular structures (capil-
lary-like structures), which seemed to be less developed
than the obvious capillary-like structures seen in the positive
control (pulp tissue) (Fig. 3C, F, I).
Stronger positive immunostaining was detected in HDPSC-
scaffold constructs cultured under osteogenic conditions,
while weaker positive staining was detected under basal con-
ditions for all endothelial markers (Fig. 3 and Table 1).
The presence and distribution of the endothelial proteins,
CD34, CD31/PECAM1, and VEGFR2, in HDPSC-scaffold
constructs implanted intraperitoneally in immunocompro-
mised nude mice for 8 weeks was also determined using
immunohistochemistry. CD34 showed the weakest staining
FIG. 2. Relative change in the levels of angiogenic marker
gene expression between human dental pulp stromal cells
(HDPSCs) cultured in monolayers and in 3D 45S5 Bioglass
for 2 and 4 weeks in vitro. The data are from HDPSCs under
osteogenic conditions, which were normalized to corre-
sponding control samples cultured under basal conditions.
These are presented as log10 of the mean of 2 -DDct – stan-
dard deviation. ***p< 0.001. Color images available online
at www.liebertpub.com/tea
FIG. 3. Immunohistochemical localization of angiogenic markers (CD34, PECAM1, and VEGFR2) in cell–scaffold
constructs cultured in vitro for 6 weeks. Light microscope images showing immunohistochemical staining for cell–scaffold
constructs cultured under basal conditions (A, D, G) or under osteogenic conditions (B, E, H) in vitro. Human pulp tissues
were used as the positive control (C, F, I). (A–C) CD34 antibodies, (D–F) PECAM1 antibodies, and (G–I) VEGFR2
antibodies. Arrows pointing to flat endothelial-like cells lining capillary-like structures in HDPS-scaffold constructs. All
sections were counterstained with Harris’ hematoxylin. Scale bar = 50 mm, except (A), for which the scale bar= 100mm.
Color images available online at www.liebertpub.com/tea
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intensity compared with CD31/PECAM1 and VEGFR2
markers in all of the constructs (Table 1). Many of the
positively stained cells seemed to align with more well-
developed microvessel-like tubular structures (Fig. 4) that
were comparable with those seen in the positive control
(pulp tissue) (Fig. 3C, F, I).
The microvessel-like tubular structures were categorized
according to their lumen size and enumerated for each of the
markers for all culture conditions in vitro and in vivo (Fig.
5A). When comparing the same positively stained different
sizes of microvessel-like tubular structures within the same
culture condition (Fig. 5A), the number of smaller (S) mi-
crovessel-like tubular structures (< 40 mm diameter) stained
positively for CD 31 was significantly higher than the pos-
itively stained larger (L) microvessel-like tubular structures
( > 40mm diameter) ( p < 0.001) in both basal and osteogenic
culture conditions and from the in vivo study. Similarly,
there were significantly higher positive CD34 ( p < 0.05) and
VGFR2 ( p < 0.01)-stained smaller microvessel-like tubular
structures than the larger one in the basal medium culture
conditions. However, there were no significant differences
in the osteogenic culture and in vivo condition ( p > 0.05).
When comparing the same positively stained and same
size of microvessel-like tubular structures between different
culture conditions (Fig. 5B), there was significantly higher
number of VEGFR2-positive-stained smaller microvessel-
like tubular structures in the basal culture condition than that
in the osteogenic culture condition ( p < 0.05). There were no
significant differences between other comparisons (Fig. 5B).
When comparing the same size of microvessel-like tu-
bular structures in the same culture condition between
different stainings (Fig. 5C), there was significantly less
number of CD34-positive-stained smaller microvessel-like
tubular structures than the CD31-positive-stained ones in
basal, osteogenic, and in vivo conditions ( p< 0.001). Simi-
larly, there was significantly less number of VEGFR2-pos-
itive-stained smaller microvessel-like tubular structures than
the CD31-positive-stained ones in only osteogenic and
in vivo conditions ( p < 0.001). There were no significant
differences between other comparisons (Fig. 5C).
Discussion
In the present study, foam replicated sintered 45S5 Bio-
glass scaffolds were produced and characterized to assess
their suitability for use in cell culture studies and ultimately
in bone tissue engineering. The characterization tests
showed that the foam replication technique produced scaf-
folds of suitable structural quality with convenient porosity
to allow cells to pass through the scaffold while maintaining
structural integrity to avoid collapse after a short immersion
period in SBF. These results uphold previous work that
showed that scaffolds fabricated by the foam replication
technique are able to be easily produced in large quantities
in a variety of shapes and sizes,25 bioactive,25 partially
crystalline,48 mechanically competent,25,42 have a suitable
porosity,25 a surface topography that promotes cell attach-
ment,40,42–44 and a chemical structure, which lends itself to
the formation of hydroxyapatite once immersed in SBF.44,45
There are increasing research efforts dedicated to under-
standing the effect that such bioactive glass scaffolds have
on vascularization of the constructs for bone tissue engi-
neering applications.26
Previously, we have demonstrated the effect of 45S5
Bioglass on osteogenic differentiation of HDPSCs.26 In this
study, we first determined gene expression of endothelial
markers by HDPSCs in monolayer culture. The resulting
pattern of endothelial marker gene expression may be at-
tributable to a number of factors. The early upregulation of
CD34 (considered by some to be hematopoietic and an early
endothelial cell marker, as well as being an early transdif-
ferentiation marker of angiogenesis) is an indication of early
angiogenic differentiation.49 This correlates well with the
lower levels of expression seen for CD31/PECAM1 and
VEGFR2 at 2 weeks and the upregulation of VEGFR2 at 4
weeks. The downregulation of these markers under os-
teoinductive conditions at 2 weeks may also be attributed to
the reported angiogenic inhibitory effects of dexamethasone
and AA2P, which are both present in the osteoinductive
culture medium.17,18,26,50
Table 1. Immunohistochemical Stain Intensity
Based Upon Blind Assessment
In vitro
Marker Basal Osteogenic In vivo
CD34 - + -
PECAM1/CD31 - / + + + + / + +
VEGFR2 + + + + / + + + +
FIG. 4. Immunohistochemical localization of angiogenic markers in a cell scaffold implanted intraperitoneally in nude
mice in vivo for 8 weeks. Light microscope images showing immunohistochemical staining of cell–scaffold constructs
implanted intraperitoneally in nude mice (A–C). (A) CD34, (B) PECAM1, (C) VEGFR2. Arrows pointing to flat endo-
thelial-like cells lining capillary-like structures. All sections were counterstained with Harris’ hematoxylin. Scale bar =
50 mm. Color images available online at www.liebertpub.com/tea
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It might also be that the pattern of gene expression ob-
served in monolayer culture is related to the lack of any
scaffold to provide an appropriate 3D microenvironment.
For this reason, endothelial marker gene expression was
investigated for HDPSCs cultured in 45S5-based Bioglass
constructs under osteogenic conditions and this was com-
pared with expression in similar controls cultured under
basal conditions. All endothelial markers (CD34, CD31/
PECAM1, and VEGFR2) were upregulated at 2 weeks and
downregulated at 4 weeks compared with the basal culture
controls, suggesting a more advanced angiogenic differen-
tiation stage for HDPSCs on 3D 45S5 Bioglass scaffolds.
Although CD34 is generally thought to be indicative of early
differentiation,49 CD34 expression was reported to be vari-
able, with different expression levels being reported in dif-
ferent tissues; and even with the different size of a given
blood vessel,51 CD31/PECAM1 and VEGFR2 are both
considered to be markers for endothelial differentiation,
proliferation, and expansion.52 Thus, their upregulation at 2
weeks in the present study suggests a more advanced stage
of angiogenic differentiation compared with cells cultured
under the same culture conditions in the monolayer. This
was followed by a decrease in expression levels at the later
time points, presumably due to a switching off of their ex-
pression as the differentiation process advanced.52 These
data also need to be considered together with the observed
significant increase in the expression of osteogenic markers
in 3D constructs compared with the monolayer culture at 2
weeks.26 This pattern of osteogenic and endothelial marker
expression is also seen as a result of signal exchange be-
tween endotheliocytes and bone cells. Bone endothelial cells
are known to respond to bone regulatory cytokine.53
Kanczler and Oreffo suggested that skeletal tissue engi-
neering requires the coculture of endothelial-derived cells as
well as osteoprogenitors to ensure adequate vascularization
of the construct and integration with the surrounding tissues.
They also suggested the use of a bioactive, angiogenic po-
rous scaffold to provide the appropriate cues, where possi-
ble, for the use of angiogenic growth factors.53 In our case,
the combination of a mixed cell population as well as the
angiogenic properties of the 45S5 Bioglass scaffold ap-
peared to accommodate these requirements as evidenced by
the expression of both osteogenic26 and endothelial markers.
The gene expression data were further supported by the
histological appearance and immunohistochemical staining
of the neotissue produced within the constructs, which
showed evidence of endothelial marker expression. For
example, under osteogenic culture conditions in vitro, en-
hanced expression of CD31/PECAM1 and VEGFR2 in
constructs was seen compared with similar constructs cul-
tured under basal conditions.
HDPSC-scaffold constructs cultured in vitro were also
seen to contain flattened endothelial-like cells curving into
microvessel-like tubular structures redolent of blood vessels.
This finding was even more pronounced when HDPSC-
scaffold constructs were implanted in vivo. Retrieved
constructs showed evidence of microvessel-like tubular
structures lined with endothelial-like cells that were posi-
tively stained for CD31/PECAM1 and VEGFR2 and were
weakly positive for CD34 compared with the less devel-
oped, microvessel-like tubular structures in their in vitro
incubated counterparts. This may be attributed to the pres-
ence of host cytokines54 in vivo, although it could also be
due to the longer incubation period compared with the
in vitro constructs. The diffusion chamber is a simple model
that allows an enclosed permissive environment to be gen-
erated within a host animal while preventing any host tissue
participation that might otherwise confound the findings.55
This model therefore restricts investigation of test parame-
ters to the implanted cells only. This ensures that any tissue
formed in the diffusion chamber is derived exclusively from
the test, not the host, cells.30,31
The findings presented in this study are in agreement with
those of Laino et al., who showed that a CD34-positive
population of HDPSCs cultured in vitro formed living au-
tologous bone chips,10 and d’Aquino et al., who confirmed
FIG. 5. The total number of small (< 40mm diameter) and large (> 40mm diameter) microvessel-like tubular structures that
were positively stained for CD34, CD31, and VEGFR2 in HDPSC-Bioglass constructs under in vitro (basal/osteogenic) and
in vivo conditions. (A) Comparison of the positive staining for same angiogenic markers between small (< 40mm) and large
(> 40mm)-diameter microvessel-like structures under the same culture conditions; (B) comparison of the positive staining for
same angiogenic markers of similar diameter microvessel-like structures under different culture conditions; (C) comparison of
the positive staining of the three different angiogenic markers of similar diameter microvessel-like structures under same
culture conditions. *p< 0.05, **p< 0.01, ****p< 0.001. Color images available online at www.liebertpub.com/tea
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the angiogenic and osteogenic synergy between osteoblasts
and endotheliocytes, both derived from HDPSCs, which
produced well-vascularized lamellar bone structures in im-
munocompromised rats.11 We categorized microvessel-like
tubular structures/blood vessels in our constructs according
to diameter size as less than 40 mm and more than 40 mm.
This particular diameter size was selected as it denotes the
maximum size for capillaries (fenestrated capillaries).34 Our
counts showed significantly higher numbers of the smaller-
sized vessels compared with larger-sized ones (Fig. 5), in-
dicating good perfusion of the constructs.
The establishment of good vascularity within in vivo
constructs is of paramount importance for tissue engineering
applications as it helps in overcoming the limitation of
construct size and necrosis that can occur in large avascu-
larized constructs, one of the major problems that need to be
addressed in tissue engineering.56
Conclusion
This study demonstrated the potential of using a combi-
nation of a suitable cell source—HDPSCs—with the
45S5Bioglass scaffold to provide a promising functional
candidate for vascularized bone tissue-engineered con-
structs.
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